Moreover, dimethyl fumarate, a drug used for decades in the treatment of psoriasis, has been identified as an NF-κB inhibitor, specifically targeting the C-terminal kinase domain of RSK [89,90]. The gene discussed is NFKB1; the disease is psoriasis.